Wanbury Limited (WANBURY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wanbury Limited (WANBURY) has a cash flow conversion efficiency ratio of -0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-56.53 Million ≈ $-611.33K USD) by net assets (Rs1.07 Billion ≈ $11.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see WANBURY market cap overview for the company's overall valuation and market capitalisation.
Wanbury Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Wanbury Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Wanbury Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wanbury Limited ranked by their cash flow conversion efficiency. Explore WANBURY cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Western Bulk Chartering AS
OL:WEST
|
0.075x |
|
Overseas Commerce Ltd
TA:OVRS
|
0.088x |
|
Ayes Celik Hasir ve Cit Sanayi AS
IS:AYES
|
-0.018x |
|
Hipages Group Holdings Ltd
AU:HPG
|
0.304x |
|
Onano Industrial Corp
TW:6405
|
-0.001x |
|
Hwa Fong Rubber (Thailand) Public Company Limited
BK:HFT
|
0.045x |
|
Mangold Fondkommission AB
ST:MANG
|
0.073x |
|
GeeCee Ventures Limited
NSE:GEECEE
|
0.109x |
Annual Cash Flow Conversion Efficiency for Wanbury Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Wanbury Limited from 2006 to 2025. View latest Wanbury Limited stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs592.72 Million ≈ $6.41 Million |
Rs261.02 Million ≈ $2.82 Million |
0.440x | +209.30% |
| 2024-03-31 | Rs279.41 Million ≈ $3.02 Million |
Rs39.78 Million ≈ $430.23K |
0.142x | +123.60% |
| 2023-03-31 | Rs-328.16 Million ≈ $-3.55 Million |
Rs197.97 Million ≈ $2.14 Million |
-0.603x | +65.13% |
| 2022-03-31 | Rs-234.20 Million ≈ $-2.53 Million |
Rs405.23 Million ≈ $4.38 Million |
-1.730x | -1520.63% |
| 2021-03-31 | Rs-1.56 Billion ≈ $-16.90 Million |
Rs166.81 Million ≈ $1.80 Million |
-0.107x | +65.30% |
| 2020-03-31 | Rs-1.43 Billion ≈ $-15.51 Million |
Rs441.33 Million ≈ $4.77 Million |
-0.308x | -116.56% |
| 2019-03-31 | Rs-2.09 Billion ≈ $-22.63 Million |
Rs297.31 Million ≈ $3.22 Million |
-0.142x | +18.93% |
| 2018-03-31 | Rs-1.85 Billion ≈ $-19.97 Million |
Rs323.65 Million ≈ $3.50 Million |
-0.175x | +38.09% |
| 2017-03-31 | Rs-1.53 Billion ≈ $-16.58 Million |
Rs433.86 Million ≈ $4.69 Million |
-0.283x | -7.32% |
| 2016-03-31 | Rs-1.63 Billion ≈ $-17.65 Million |
Rs430.53 Million ≈ $4.66 Million |
-0.264x | -16.35% |
| 2015-03-31 | Rs-1.77 Billion ≈ $-19.16 Million |
Rs401.67 Million ≈ $4.34 Million |
-0.227x | +17.67% |
| 2014-03-31 | Rs-1.65 Billion ≈ $-17.85 Million |
Rs454.48 Million ≈ $4.92 Million |
-0.275x | +92.09% |
| 2013-03-31 | Rs-212.95 Million ≈ $-2.30 Million |
Rs741.21 Million ≈ $8.02 Million |
-3.481x | -980.07% |
| 2012-03-31 | Rs711.13 Million ≈ $7.69 Million |
Rs281.25 Million ≈ $3.04 Million |
0.395x | +747.00% |
| 2011-03-31 | Rs1.05 Billion ≈ $11.35 Million |
Rs49.02 Million ≈ $530.13K |
0.047x | -78.40% |
| 2010-03-31 | Rs1.92 Billion ≈ $20.81 Million |
Rs416.05 Million ≈ $4.50 Million |
0.216x | -52.49% |
| 2009-03-31 | Rs1.58 Billion ≈ $17.13 Million |
Rs720.95 Million ≈ $7.80 Million |
0.455x | +318.55% |
| 2007-03-31 | Rs1.29 Billion ≈ $13.96 Million |
Rs-268.83 Million ≈ $-2.91 Million |
-0.208x | -346.01% |
| 2006-03-31 | Rs1.01 Billion ≈ $10.94 Million |
Rs-47.21 Million ≈ $-510.60K |
-0.047x | -- |
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more